868692-49-3

Basic information

• Product Name: 4-fluoro-2-iodo-5-(trifluoromethyl)benzenamine
• Synonyms: 4-fluoro-2-iodo-5-(trifluoromethyl)benzenamine;4-Fluoro-2-iodo-5-trifluoromethyl-phenylamine
• CAS NO: 868692-49-3
• Molecular Formula: C₇H₄F₄IN
• Molecular Weight: 305.01
• Mol File: 868692-49-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 256.5°C at 760 mmHg
• Flash Point: 109°C
• Appearance: /
• Density: 2.013g/cm³
• Vapor Pressure: 0.0153mmHg at 25°C
• Refractive Index: 1.551
• CAS DataBase Reference: 4-fluoro-2-iodo-5-(trifluoromethyl)benzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-fluoro-2-iodo-5-(trifluoromethyl)benzenamine(868692-49-3)
• EPA Substance Registry System: 4-fluoro-2-iodo-5-(trifluoromethyl)benzenamine(868692-49-3)

Safety Data

• Hazardous Substances Data: 868692-49-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H4F4IN/c8-4-2-5(12)6(13)1-3(4)7(9,10)11/h1-2H,13H2

Upstream product

• 2357-47-3 4-Fluoro-3-trifluoromethylaniline 

Downstream Products

• 868692-48-2 N-(4-fluoro-2-iodo-5-trifluoromethyl-phenyl)-bis-methanesulfonamide 

Relevant articles and documents

Chagas Disease Drug Discovery: Multiparametric Lead Optimization against Trypanosoma cruzi in Acylaminobenzothiazole Series

Acylaminobenzothiazole hits were identified as potential inhibitors of Trypanosoma cruzi replication, a parasite responsible for Chagas disease. We selected compound 1 for lead optimization, aiming to improve in parallel its anti-T. cruzi activity (IC50 = 0.63 μM) and its human metabolic stability (human clearance = 9.57 mL/min/g). A total of 39 analogues of 1 were synthesized and tested in vitro. We established a multiparametric structure-activity relationship, allowing optimization of antiparasite activity, physicochemical parameters, and ADME properties. We identified compound 50 as an advanced lead with an improved anti-T. cruzi activity in vitro (IC50 = 0.079 μM) and an enhanced metabolic stability (human clearance = 0.41 mL/min/g) and opportunity for the oral route of administration. After tolerability assessment, 50 demonstrated a promising in vivo efficacy.

Novel indole derivatives as selective androgen receptor modulators (SARMS)

The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.